Cero Therapeutics Faces Nasdaq Delisting Warning

TL;DR

Nasdaq's kicking Cero Therapeutics off the exchange, company's fighting back.

AI Summary

Cero Therapeutics Holdings, Inc. announced on October 24, 2024, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing requirements. The company is currently evaluating the notice and plans to respond to the Nasdaq staff.

Why It Matters

This filing signals potential delisting from Nasdaq, which could significantly impact the company's stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — Receiving a delisting notice from a major stock exchange like Nasdaq poses a significant risk to the company's continued operation and investor value.

Key Players & Entities

• Cero Therapeutics Holdings, Inc. (company) — Registrant
• Nasdaq Stock Market (company) — Exchange issuing delisting notice

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CERO NASDAQ Global Market
• $1.00 — common stock has been below the minimum $1.00 per share required for continued listin
• $0.10 — common stock had a closing bid price of $0.10 or less for ten consecutive trading day

Filing Documents

• ea0218621-8k_cerothe.htm (8-K) — 30KB
• 0001213900-24-090831.txt ( ) — 245KB
• cero-20241024.xsd (EX-101.SCH) — 4KB
• cero-20241024_def.xml (EX-101.DEF) — 26KB
• cero-20241024_lab.xml (EX-101.LAB) — 36KB
• cero-20241024_pre.xml (EX-101.PRE) — 25KB
• ea0218621-8k_cerothe_htm.xml (XML) — 6KB

01 Notice of Delisting or Failure to Satisfy a Continued

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on July 19, 2024, CERo Therapeutics Holdings, Inc., a Delaware corporation (the " Company "), received a letter (the " Bid Price Requirement Letter ") from the staff at The Nasdaq Global Market (" Nasdaq ") notifying the Company that, for the 30 consecutive trading days prior to the date of the Bid Price Requirement Letter, the closing bid price for the Company's common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market set forth in Nasdaq Listing Rule 5450(a)(1), which is required for continued listing of the Company's common stock on Nasdaq (the " Bid Price Requirement "). In accordance with applicable Nasdaq listing rules, the Company had 180 calendar days, or until January 15, 2025, to regain compliance with the Bid Price Requirement (the " Bid Price Cure Period "). On October 24, 2024, the Company received another letter (the " Low Price Deficiency Letter ") from Nasdaq notifying the Company that, as of October 24, 2024, the common stock had a closing bid price of $0.10 or less for ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the " Low Priced Stocks Rule "). As a result, Nasdaq has determined to delist the Company's securities from The Nasdaq Global Market, notwithstanding the Bid Price Cure Period, which is rendered unavailable by the Low Priced Stocks Rule. The Company has the right to appeal Nasdaq's determination by October 31, 2024. The Company intends to appeal such determination before a panel (the " Hearings Panel "). The hearing request will stay the suspension of the trading of the Company's common stock pending such hearing or any extension provided by the Hearings Panel. At such hearing, the Company intends to submit a plan to regain compliance with the Bid Price R

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 25, 2024 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Interim Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR